Table 4 Relationships between the protein expressions and clinicopathological factors in advanced-stage diseases
Stages III–IV (n=41) | P53 | Phospho-p53 | Wip1 | Nuclear phospho-p38 | Cytoplasmic phospho-p38 | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Positive | Negative | High | Low | High | Low | High | Low | High | Low | ||||||
n=14 | n=27 | p-value | n=38 | n=3 | p-value | n=5 | n=36 | p-value | n=38 | n=3 | p-value | n=30 | n=11 | p-value | |
Age ≥60 | 6 (43%) | 8 (30%) | 0.49 | 13 (34%) | 1 (33%) | 1 | 1 (20%) | 13 (36%) | 0.64 | 13 (34%) | 1 (33%) | 1 | 12 (40%) | 2 (18%) | 0.28 |
FIGO stage IV | 5 (36%) | 8 (30%) | 0.73 | 13 (34%) | 0 (0%) | 0.54 | 2 (40%) | 11 (31%) | 0.64 | 13 (34%) | 0 (0%) | 0.54 | 7 (23%) | 6 (55%) | 0.073 |
Pure histology | 11 (79%) | 24 (89%) | 0.39 | 32 (84%) | 3 (100%) | 1 | 5 (100%) | 30 (83%) | 1 | 33 (87%) | 2 (67%) | 0.39 | 26 (87%) | 9 (82%) | 0.65 |
Lymph node metastasis | 5 (36%) | 15 (56%) | 0.33 | 20 (53%) | 0 (0%) | 0.23 | 2 (40%) | 18 (50%) | 1 | 20 (53%) | 0 (0%) | 0.23 | 16 (53%) | 4 (36%) | 0.48 |
Positive peritoneal cytology | 12 (86%) | 23 (85%) | 1 | 32 (84%) | 3 (100%) | 1 | 4 (80%) | 31 (86%) | 0.57 | 32 (84%) | 3 (100%) | 1 | 26 (87%) | 9 (82%) | 0.65 |
Endometriosis present | 5 (36%) | 11 (41%) | 1 | 15 (39%) | 1 (33%) | 1 | 3 (60%) | 13 (36%) | 0.36 | 16 (42%) | 0 (0%) | 0.27 | 11 (37%) | 5 (45%) | 0.72 |
Residual tumor present | 5 (36%) | 13 (48%) | 0.52 | 15 (39%) | 3 (100%) | 0.077 | 2 (40%) | 16 (44%) | 1 | 16 (42%) | 2 (67%) | 0.57 | 10 (33%) | 8 (73%) | 0.036 |
Lymphadenectmy undone | 4 (29%) | 12 (44%) | 0.50 | 14 (37%) | 2 (67%) | 0.55 | 1 (20%) | 15 (42%) | 0.63 | 15 (39%) | 1 (33%) | 1 | 10 (33%) | 6 (55%) | 0.29 |